肺微生物组,转录组和Mycoplasma pneumoniae pneumoniae中临床结果的综合性研究
Xia Huang1, Yingying Luo1, Jing Wang1
1Department of Respiratory Medicine, Children's Hospital of Nanjing Medical University, Nanjing, 210008, China.
Respiratory research
|January 18, 2024
概括
在儿童中,复杂的Mycoplasma pneumoniae肺炎 (MPP) 显示了肺部微生物组的破坏. 病原体,肺微生物组和宿主反应之间的相互作用会影响MPP的严重程度和恢复.
科学领域:
- 儿科呼吸系统医学 儿科呼吸系统医学
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 菌性肺炎肺炎 (MPP) 是一个常见的儿童呼吸道感染.
- 了解病原体,肺微生物组和宿主反应之间的相互作用对于管理MPP至关重要.
- 不同的临床表现,一般的MPP (GMPP) 和复杂的MPP (CMPP),表明潜在的生物学差异.
研究的目的:
- 调查病原体,肺微生物组和儿科MPP中的宿主反应之间的相互作用.
- 为了将这些相互作用与疾病严重程度和临床结果相关联.
- 将这些元素区分为MPP的一般形式和复杂形式.
主要方法:
- 预期从41名患有MPP的儿童收集支气管支气管洗液.
- 肺液的微生物组和转录基因分析.
- 发现与临床特征和结果的相关性,区分GMPP和CMPP.
主要成果:
- 复杂的MPP (CMPP) 呈现出Mycoplasma pneumoniae (MP) 的相对丰度增加和肺微生物群多样性减少.
- 宿主基因分析确定了与中性粒细胞功能和炎症途径相关的关键模块.
- 一个特定的肺微生物组和宿主响应特征,与高MP丰度相关,与CMPP相关,以及长时间的成像恢复.
结论:
- 与GMPP相比,患有CMPP的患者肺部微生物组更受干扰.
- MP,肺微生物组和宿主反应之间的相互作用与儿童的MPP严重程度和结果密切相关.
- 这些发现突出了改善儿科MPP管理的潜在治疗目标.
更多相关视频
04:32Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
11.8K
07:43A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice
Published on: September 28, 2016
9.1K
相关概念视频
01:30Pneumonia III: Complications and Assessment
227
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
227
01:30Pneumonia I: Introduction
239
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
239
01:28Pneumonia IV: Management
331
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
331
01:29Pneumonia II: Pathophysiology
278
The pathophysiology of pneumonia involves the following steps:
278